Detalhe da pesquisa
1.
A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.
Mol Ther
; 31(12): 3564-3578, 2023 Dec 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37919903
2.
Immunological ignorance is an enabling feature of the oligo-clonal T cell response to melanoma neoantigens.
Proc Natl Acad Sci U S A
; 116(47): 23662-23670, 2019 11 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-31685621
3.
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma.
Cancer Immunol Immunother
; 68(4): 609-618, 2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-30721341
4.
RNA-seq for identification of therapeutically targetable determinants of immune activation in human glioblastoma.
J Neurooncol
; 141(1): 95-102, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30353265
5.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
N Engl J Med
; 372(21): 2006-17, 2015 May 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-25891304
6.
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.
Lancet Oncol
; 17(10): 1374-1385, 2016 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-27592805
7.
Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial.
Lancet Oncol
; 17(11): 1558-1568, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27622997
8.
Health-related quality of life in patients with malignant melanoma by stage and treatment status.
J Am Acad Dermatol
; 85(2): 486-489, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-29906543
9.
Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.
Lancet Oncol
; 16(4): 375-84, 2015 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-25795410
10.
Phase 2 study of sunitinib in patients with metastatic mucosal or acral melanoma.
Cancer
; 121(22): 4007-15, 2015 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-26264378
11.
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Blood
; 122(6): 863-71, 2013 Aug 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-23770775
12.
Amino-terminal extended peptide single-chain trimers are potent synthetic agonists for memory human CD8+ T cells.
J Immunol
; 188(12): 5839-49, 2012 Jun 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22573808
13.
Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
J Cutan Pathol
; 41(7): 568-75, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24641301
14.
Effect of selumetinib vs chemotherapy on progression-free survival in uveal melanoma: a randomized clinical trial.
JAMA
; 311(23): 2397-405, 2014 Jun 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-24938562
15.
Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.
Clin Cancer Res
; 30(10): 2017-2024, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38266167
16.
Improved survival with ipilimumab in patients with metastatic melanoma.
N Engl J Med
; 363(8): 711-23, 2010 Aug 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-20525992
17.
Metastatic melanoma after solid organ transplantation: An interdisciplinary, institution-based review of management with systemic and targeted therapies.
J Am Acad Dermatol
; 78(1): 184-185, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-29241778
18.
Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma.
Mol Ther
; 20(10): 1998-2003, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22871663
19.
Phase I Trial of Autologous RNA-electroporated cMET-directed CAR T Cells Administered Intravenously in Patients with Melanoma and Breast Carcinoma.
Cancer Res Commun
; 3(5): 821-829, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37377890
20.
Anti-BCMA/CD19 CAR T Cells with Early Immunomodulatory Maintenance for Multiple Myeloma Responding to Initial or Later-Line Therapy.
Blood Cancer Discov
; 4(2): 118-133, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36413381